To identify risk factors associated with bleeding in patients who received alteplase for pulmonary embolism (PE), with a specific focus on risk factors available to the clinician at the time thrombolytics are being considered.Case-control study.Large academic medical center.Sixty-two adults with PE who were administered alteplase 100 mg over a 2-hour infusion period between January 2000 and October 2011; of these patients, 28 experienced major bleeding (case patients), and 34 did not develop major bleeding (control patients).Risk factors for bleeding from alteplase were compiled from the U.S. product label and the literature. Multivariate logistic regression analysis was used to assess for risk factors independently associated with bleeding. Patients with major bleeding more frequently had recent major surgery (odds ratio [OR] 9.00, 95

作者：Garrett M, Curtis；Simon W, Lam；Anita J, Reddy；Seth R, Bauer

来源：Pharmacotherapy 2014 年 34卷 8期